XTX Topco Ltd lowered its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 56.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,223 shares of the biotechnology company's stock after selling 26,970 shares during the quarter. XTX Topco Ltd's holdings in Veracyte were worth $840,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Jones Financial Companies Lllp lifted its stake in Veracyte by 49.7% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 237 shares during the last quarter. US Bancorp DE raised its stake in Veracyte by 57.4% during the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after acquiring an additional 647 shares during the period. Principal Securities Inc. boosted its stake in Veracyte by 34.1% in the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 485 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Veracyte during the 4th quarter worth approximately $91,000. Finally, Sterling Capital Management LLC lifted its holdings in shares of Veracyte by 810.2% in the 4th quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 2,155 shares during the last quarter.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the company. UBS Group raised their target price on Veracyte from $46.00 to $49.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Stephens restated an "overweight" rating and issued a $45.00 target price on shares of Veracyte in a research report on Wednesday, March 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $51.00 price target on shares of Veracyte in a report on Tuesday, February 25th. StockNews.com downgraded Veracyte from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Craig Hallum initiated coverage on Veracyte in a research report on Thursday, March 20th. They issued a "buy" rating and a $45.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, Veracyte has a consensus rating of "Moderate Buy" and a consensus price target of $42.60.
Read Our Latest Report on Veracyte
Veracyte Trading Up 2.4 %
VCYT stock traded up $0.72 on Tuesday, hitting $31.32. 219,687 shares of the company's stock traded hands, compared to its average volume of 857,585. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -208.80 and a beta of 2.03. Veracyte, Inc. has a 1-year low of $19.09 and a 1-year high of $47.32. The stock has a fifty day moving average of $32.95 and a 200-day moving average of $37.39.
Veracyte (NASDAQ:VCYT - Get Free Report) last released its earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The business had revenue of $118.63 million for the quarter, compared to the consensus estimate of $110.73 million. During the same period last year, the firm posted ($0.39) earnings per share. On average, equities research analysts anticipate that Veracyte, Inc. will post 0.68 earnings per share for the current fiscal year.
About Veracyte
(
Free Report)
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
Featured Stories
Before you consider Veracyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.
While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
